SCHEMBL5388340

SCHEMBL5388340

CN1CC[C@H](OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1

nearest known ligand 0.98

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.98
CYP1A2 P05177 1/20 0.98
CYP3A4 P08684 2/20 0.87
CYP2D6 P10635 1/20 0.87
CHRM3 P20309 8/20 0.61
CHRM2 P08172 3/20 0.61
CHRM1 P11229 3/20 0.60
CHRM4 P08173 2/20 0.60
CHRM5 P08912 2/20 0.60
HRH1 P35367 2/20 0.60
KCNH2 Q12809 2/20 0.60
HTR2B P41595 1/20 0.60
HTT P42858 1/20 0.54
SLC29A1 Q99808 1/20 0.53
LMNA P02545 1/20 0.52
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385056 1.00 ALDH1A1 (0.98) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL5388335 1.00 ALDH1A1 (0.98) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL5385053 1.00 ALDH1A1 (0.98) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL6981090 1.00 ALDH1A1 (0.98) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL10098821 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL1697179 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL5391762 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL5391765 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL5395653 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3
SCHEMBL418425 0.99 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253182-B2 Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments SOFOTEC GMBH & CO. KG (DE) 2007-08-07 US disclosed
US-6613795-B2 Respiratory system disorders; muscle relaxants Noe, Christian (DE) 2003-09-02 US disclosed
US-20020173536-A1 Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments CHRISTIAN NOE AND ERNST MUTSCHLER 2002-11-21 US disclosed
US-6307060-B1 ANTISPASMODIC AGENTS Noe, Christian 2001-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173536-A1 Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments CYP2A13, CYP3A43, HCAR2 ALDH1A1 505/4885CYP1A2 17/4885CYP3A4 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.